Weight loss "stalling" on GLP1s?

What happens when weight loss stalls on GLP1s? We check around the GLP1 community to see what people have figured out.

The UK's bet on GLP1

A look at the UK's growing evaluation and use of GLP1 receptor agonists -- Ozempic, Mounjaroy, Wegovy, Zepbound and more.

Research on GLP1 Signaling in the brain

How does GLP1 signal the brain? We take a look at related research to try and learn more.

GLP1s and Osteoarthritis

Newly published research explores the link between Osteoarthritis and GLP1s -- positive results that are somewhat predictable.

Viking Therapeutic's new GLP1 impresses at ObesityWeek 2024

At ObesityWeek 2024, Viking Therapeutic showed study results on their new drug VK2735 -- 8% body weight loss at 28 days, in the highest dose.

Semaglutide's link to blinding disease (NAION)

We explore the link between blinding disease/vision loss and Semaglutide, as reported by medical research.

Patent expirations for GLP1 Receptor Agonists

How long will we have to wait for generic versions of GLP1 drugs? We take a look at patent expiry dates for the most popular brands & GLP1 formulations.

FDA reconsidering Tirzepatide shortage list removal

After legal action by a group of compounders, the FDA is reviewing their removal of Tirzepatide (Mounjaro, Zepbound) from the shortage list.

Compounders sue FDA over Tirzepatide shortage changes

Compounders sue FDA for removing Eli Lilly's weight loss drug from the shortage list. Does the case have legs?

Why the Tirzepatide shortage ending might be bad news.

Bad news that sounds like good news: FDA ends shortage Eli Lilly's GLP-1 (Tirzepatide). We'll tell you why that's bad news.

GLP1s and Sleep Apnea

GLP1s (in particular Tirzepatide, created by Eli Lilly) have positive effects on Sleep Apnea

Habener, Mosjov and Knudsen win the Lasker award

The current GLP1 receptor agonist boom was made possible by the work of Joel Habener, Lotte Bjerre Knudsen, and Svetlana Mojsov.